This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haas, A. R. Articles by Albelda, S. M. Search for Related Content PubMed PubMed Citation Articles by Haas, A. R. Articles by Albelda, S. M.

Cycloxygenase-2 Inhibition Augments the Efficacy of a Cancer Vaccine

Authors' Affiliation: Thoracic Oncology Research Laboratory, Philadelphia, Pennsylvania

Requests for reprints: Steven Albelda, Thoracic Oncology Research Laboratory, BRB II/III, 421 Curie Boulevard, Philadelphia, PA 19104-6160. Phone: 215-573-9933; Fax: 215-573-4469; E-mail: Albelda{at}mail.med.upenn.edu.

Tumor-derived cyclooxygenase-2 (COX-2) and its product, prostaglandin E₂, exert strong immunoinhibitory effects that block dendritic cell function and CD4⁺ and CD8⁺ T-cell proliferation and function. We have shown previously that the addition of an oral COX-2 inhibitor to immunogene therapy using IFN-ß markedly augmented therapeutic efficacy in murine tumor models. In this study, we hypothesized that COX-2 inhibition might also augment an antitumor vaccination strategy. Mice bearing tumors derived from TC1 cells, a tumor line that expresses the human papillomavirus (HPV) E7 protein, were thus vaccinated with an adenoviral vector expressing HPV E7 protein (Ad.E7). This vaccine approach effectively generated E7-specific CD8⁺ cells and slowed the growth of small tumors but had little effect on large tumors. However, feeding mice with the COX-2 inhibitor, rofecoxib, restored the effectiveness of the vaccine against large tumors and prolonged survival. This effect was accompanied by a larger percentage of E7-specific CD8⁺ cells in the regional draining lymph nodes and a markedly increased number of tumor-infiltrating E7-specific CD8⁺ cells (as determined by flow cytometry) and total CD8⁺ T cells (as determined by immunohistochemical staining). Increased immunocyte trafficking was likely mediated by the generation of a Th1-type tumor microenvironment because COX-2 inhibition increased expression levels of mRNA for IFN-, interleukin-12, IP-10, and MIG while lowering the expression of vascular endothelial growth factor within tumors. This study shows that the effectiveness of a cancer vaccine can be significantly improved by adding COX-2 inhibition.

This article has been cited by other articles:

				D. Schaue, B. Comin-Anduix, A. Ribas, L. Zhang, L. Goodglick, J. W. Sayre, A. Debucquoy, K. Haustermans, and W. H. McBride T-Cell Responses to Survivin in Cancer Patients Undergoing Radiation Therapy Clin. Cancer Res., August 1, 2008; 14(15): 4883 - 4890. [Abstract] [Full Text] [PDF]

				J. E. Talmadge Pathways Mediating the Expansion and Immunosuppressive Activity of Myeloid-Derived Suppressor Cells and Their Relevance to Cancer Therapy Clin. Cancer Res., September 15, 2007; 13(18): 5243 - 5248. [Abstract] [Full Text] [PDF]

				P. Sinha, V. K. Clements, A. M. Fulton, and S. Ostrand-Rosenberg Prostaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells Cancer Res., May 1, 2007; 67(9): 4507 - 4513. [Abstract] [Full Text] [PDF]

				E. P. Ryan, C. M. Malboeuf, M. Bernard, R. C. Rose, and R. P. Phipps Cyclooxygenase-2 Inhibition Attenuates Antibody Responses against Human Papillomavirus-Like Particles J. Immunol., December 1, 2006; 177(11): 7811 - 7819. [Abstract] [Full Text] [PDF]

				P. Mrass, H. Takano, L. G. Ng, S. Daxini, M. O. Lasaro, A. Iparraguirre, L. L. Cavanagh, U. H. von Andrian, H. C.J. Ertl, P. G. Haydon, et al. Random migration precedes stable target cell interactions of tumor-infiltrating T cells J. Exp. Med., November 27, 2006; 203(12): 2749 - 2761. [Abstract] [Full Text] [PDF]